Nexus - 0305 - New Times Magazine-pages

Page Content (OCR)

| — Hormone Heresy: Oestrogen's Deadly Truth — In a 1995 study published in the Journal thereby protecting the breast tissue from of Fertility and Sterility, researchers did a _ the cancer-promoting oestrogens present in Johns Hopkins Private Obstetrics and double-blind randomised study examining the body. A growing number of doctors Gynecology Clinic accumulated 40 years the use of topical progesterone cream _ insist that the same results can be achieved of research which was published in the and/or topical oestrogen in regard to breast _ by giving natural progesterone. American Journal of Epidemiology in cell growth. The results showed that Uterine cancer is one of the possible 1981.2 What they discovered was that, women using progesterone had dramatical- side-effects of Tamoxifen. One study when the low-progesterone group was ly reduced cell-multiplication rates com- showed that 27 per cent of women taking compared to the normal-progesterone pared to the women using either the place- Tamoxifen showed hyperplastic group, the occurrence of breast cancer was bo or oestrogen. The women using only (unfavourable new growth) changes in their 5.4 times greater in the women in the low- oestrogen had significantly higher cell mul- wombs within 15 months.* progesterone group. That is, the incidence tiplication rates than any of the other Tamoxifen is carcinogenic and can cause of breast cancer in the low-progesterone groups. The women using a combination an early menopause, osteoporosis, endome- group was over 80 per cent greater than in of progesterone and oestrogen were closer trial cancer, liver cancer and clotting dis- the normal-progesterone group. to the placebo group.” ease. Taking 20 milligrams of Tamoxifen When the study looked at the low-prog- This exciting study provides some of the _ per day can increase the risk for developing esterone group for all types of cancer, they first direct evidence that oestradiol signifi- endometrial cancer by up to five times. found that women in this group experi- cantly increases breast cell growth, and that Clotting disorders are seven times more enced a tenfold increase for all malignant progesterone impressively decreases cell frequent. One study showed just a meagre cancers, compared to the normal-proges- proliferation rates even when oestrogen is 0.7 per cent benefit for women taking terone group. This would suggest that hav- also supplemented. Tamoxifen preventively to reduce the risk ing a normal level of progesterone protect- At this point, it's important to explore the of developing further tumours in the ed women from nine-tenths of all cancers implications of the experimental drug _ breast.” that might otherwise have occurred.” Tamoxifen which is being prescribed to It is also interesting to note that menstru- It is interesting to note that the study dis- women with breast cancer. Since it is pro- ating women who have breast surgery car- appeared into oblivion when there was no _ posed to have anti-oestrogenic effects, itis ried out during the second half of their money available to pursue the obvious used as a breast cancer treatment since it menstrual cycle—the luteal phase, when implications of a progesterone-deficiency blocks the uptake of oestradiol and progesterone is high in order to balance role in cancer. oestrone (the cell-proliferating oestrogens), oestrogens—survive far longer than do Johns Hopkins Private Obstetrics and Gynecology Clinic accumulated 40 years of research which was published in the American Journal of Epidemiology in 1981.% What they discovered was that, when the low-progesterone group was compared to the normal-progesterone group, the occurrence of breast cancer was 5.4 times greater in the women in the low- progesterone group. That is, the incidence of breast cancer in the low-progesterone group was over 80 per cent greater than in the normal-progesterone group. When the study looked at the low-prog- esterone group for all types of cancer, they found that women in this group experi- enced a tenfold increase for all malignant cancers, compared to the normal-proges- terone group. This would suggest that hav- ing a normal level of progesterone protect- ed women from nine-tenths of all cancers that might otherwise have occurred.” It is interesting to note that the study dis- appeared into oblivion when there was no money available to pursue the obvious implications of a progesterone-deficiency role in cancer. NEXUS ¢ 69 Continued from page 26 AUGUST-SEPTEMBER 1996